Factors associated with human papillomavirus infection among women in the Northwest Territories.
Brassard, Paul ; Jiang, Ying ; Severini, Alberto 等
Cervical cancer is the second leading cause of cancer-related
deaths among women worldwide. Human papillomavirus (HPV) has been found
to be the precursor for cervical cancer in 99% of the cases. Global HPV
prevalence among women is estimated at 10%, with approximately 75% of
the female population acquiring an HPV infection at least once in their
lives. Furthermore, some population groups appear to be at higher risk
for infection than others. (1,2)
In Canada, approximately 1,300 new cervical cancer cases are
diagnosed each year and 380 deaths are due to the disease. (1) In some
regions, Aboriginal women have higher rates of cervical cancer compared
to other Canadian women. (3-6) Data from Manitoba show that in
comparison with non-Aboriginal women, Aboriginal women had 1.8 and 3.6
times the age-standardized incidence rates of in situ and invasive
cervical cancer, respectively. (4) In addition to oncogenic high-risk
HPV (HR-HPV), several co-factors are needed in cervical carcinogenesis
and little data are available regarding the determinants of HPV
infection in the Aboriginal population of Canada. (7)
Aboriginal groups make up approximately half of the population of
the Northwest Territories (NWT). (8) A recent study among women in the
NWT found that HPV prevalence was approximately 50% higher among
Aboriginal than non-Aboriginal women (28% versus 18.8%, respectively).
(9) We wished to examine co-factors associated with HR-HPV infection in
a population of women (both Aboriginal and non-Aboriginal) in the
Northwest Territories. The identification of various factors associated
with high-risk HPV could help in the planning of cervical cancer
prevention and intervention programs in this region. (10-12)
METHODS
This cross-sectional design consisted of a convenience sample of
all women aged 14 years or older presenting for a Papanicolaou (Pap)
test across all regions of the NWT from March 2009 to March 2010.
Participants were asked by their local health care provider to complete
a questionnaire and to give written consent to both the questionnaire
and HPV testing. Refusals to participate were not tabulated. The
questionnaire consisted of 20 short multiple-choice questions and
collected information known to be associated with HPV infection such as
demographic characteristics, sexual behaviour, and gynaecological and
obstetrical events. It was self-administered and reviewed by the health
care provider in order to ensure completeness and to clarify any
misunderstandings the study participant may have.
To avoid repeated measures, if more than one Pap test was performed
over the study period, only the first sample (and accompanying
questionnaire) was kept for analysis. Universal coverage of health care
is present in the NWT, thus there are no other Pap test providers in the
area. As of 2008, 88% of NWT women aged 18-69 reported having had a Pap
test in the previous 3 years. (8)
Samples were collected through liquid-based cervical scrapes,
stored in the NWT regional laboratory, and shipped to the
[DynaLIFE.sub.Dx] Laboratory in Edmonton, Canada. Approximately half of
the medium was retained for Pap testing. The remainder was shipped to
the Public Health Agency of Canada National Microbiology Laboratory
(NML) in Winnipeg, Canada for HPV typing.
HPV types are classified as being high-risk (HR) or low-risk (LR)
based on their oncogenic potential in cervical cancer. (13)
HPV typing was done using a Luminex assay, a method developed at
the NML in Canada which detects 46 HPV types. (14,15) These include 24
of the 25 IARC high-risk (HR) types found in group 1, 2a, and 2b (HPV
16, 18, 26, 30, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68,
69, 70, 73, 82, 85 and 97) as well as 22 types considered of low (LR) or
unknown risk (6, 11, 13, 32, 40, 42, 43, 44, 54, 61, 62, 71, 72, 74, 81,
83, 84, 86, 87, 89, 90, and 91). (13) The sensitivity and specificity of
the NML Luminex assay, using direct sequencing as a gold standard, were
98.8% and 96.4%, respectively. (15,16)
When present, contraception methods were classified as either
hormonal-based or non-hormonal. Birth control pills and
medroxy-progesterone injections were classified as hormonal, while IUDs,
condoms, diaphragms, and tubal ligations were classified as
non-hormonal. Sexually transmitted infections are reported as a subset
for participants who answered "yes" to ever having had an STI.
STI categories were not mutually exclusive as participants could report
having had more than one STI. Lifetime number of sexual partners was
dichotomized based on the median distribution. Grade school was defined
as attendance from grades 1 through 12. The number of lifetime
deliveries was reported as the number of live birth deliveries.
Univariate unconditional logistic regression was performed on all
independent variables to assess their association with HR-HPV infection.
Multivariate analysis was conducted on variables found statistically
significant on univariate analysis results and predictors of HR-HPV
infection that were identified in previous literature. Odds ratios (ORs)
and their associated 95% confidence intervals (CIs) were calculated.
Findings were considered to be statistically significant when the
2-sided p-value was [less than or equal to]0.05.
Ethics approval was obtained from the Health Canada Ethics Review
Board, McGill University, and Stanton Territorial Health Authority. A
license to conduct research was also obtained from the Aurora Research
Institute in accordance with the NWT Scientists Act.
RESULTS
A total of 1,279 women participated in this study. Overall, 478
(37.4%) participants self-identified as Aboriginal and 677 (52.9%)
self-identified as non-Aboriginal (9.7% had missing information on their
cultural background). Among the Aboriginal women, 286 (59.8%) were of
First Nations origin, 138 (28.9%) were Metis and 54 (11.3%) were Inuit.
Most women were married or living with a partner (65.1%), had either
grade school or community college education (63.4%), reported at least
one full-term pregnancy (59.6%), and reported one sexual partner in the
past year (72.1%).
When comparing our sample of women to the Canadian 2006 Census
results for the NWT, our study had a statistically significant larger
coverage of more educated, married, and younger women, as well as a
smaller representation of Aboriginal women. Our participants matched the
NWT general population on smoking and employment. (17)
Of the 1,279 participants, there were 178 (13.9%) women with
missing HPV results (sample mislabelled or lost during transport). These
were excluded from the logistic regression analysis. For the remaining
1,101 women, overall HR-HPV prevalence was 14.2%. HR-HPV was most
prevalent among women aged 20 years or less (30.2%), with decreasing
prevalence with increasing age (Table 1).
We examined co-factors of HR-HPV infection for the entire cohort in
univariate and multivariate analysis. In the multivariate model,
increasing age and number of lifetime deliveries were protective, while
single marital status, Aboriginal background, use of hormonal
contraceptives, current smoking, and the number of sexual partners in
the last year increased the risk of prevalent HR-HPV (Table 1).
We then explored the co-factors for HR-HPV among women of
Aboriginal background (First Nations, Metis and Inuit) and among
non-Aboriginal women in the NWT (Tables 2 and 3). In multivariate
analysis, only the number of lifetime deliveries was found to be
protective of prevalent HR-HPV in non-Aboriginal women. In Aboriginal
women, being single, hormonal contraception, current smoking, and age at
first sexual intercourse were significant risk factors, while increasing
age and number of lifetime deliveries were found to be protective. Among
Aboriginal women, no difference in risk of HR-HPV infection was noted
for the three different cultural groups.
DISCUSSION
This study demonstrates the differences in predictors of HR-HPV
infection for different population groups. Aboriginal women were more
than twice as likely to have HR-HPV as non-Aboriginal women (OR=2.40,
95% CI: 1.65-3.49, Table 1). It is important to note that between the
different cultural groups of Aboriginal women in the NWT, there was no
group that was more at risk than another. Overall, ever having had a
sexually transmitted infection (STI) was not associated with a higher
risk for HR-HPV, although this has been previously identified as a
predictor of HPV infection. (12) We recorded self-reported information
and may be dealing with a recall bias influencing our results. We also
observed a decrease in risk of HPV infection with an increase in parity.
Previous studies have reported similar findings. (18,19) However, some
studies have reported an increase in risk with number of births. (20)
More studies are needed to better conclude the effects of parity on the
risk of HPV infection.
Overall, the number of sexual partners in the previous year was
more indicative of current infection than was the number of lifetime
partners. When we looked at this characteristic by Aboriginal status,
although showing a clear trend in both groups, the number of sexual
partners in the previous year did not reach statistical significance
after adjusting for covariates.
Selection bias is a potential limitation associated with
convenience sampling and could have influenced our findings. Our study
had a larger coverage of more educated, married, and younger women, and
a smaller representation of Aboriginal women than the overall NWT
population. Women who participated in this study were those who
presented for a Pap test and therefore, they could be prone to more
preventive behaviour and healthier lifestyles than the general
population. However, as of 2008, 88% of NWT women aged 18-69 reported
having had a Pap test in the previous three years. (7) As very few women
do not access the service over a three-year period, we can consider our
sample somewhat representative in terms of accessing time-appropriate
cervical cancer screening. Although recent literature is showing a
pattern of increasing cervical cancer screening coverage among several
different Aboriginal populations across Canada, (21) there is still
cause for concern, given that there is a high prevalence of HR-HPV in
this population. Additionally, it is not yet clear if the increase in
screening rates will lead to a reduction in cervical cancer incidence
and mortality if high-risk subsets of the population are systematically
underscreened for cervical cancer. Unfortunately, we were not able to
explore coverage according to geographical areas in the NWT as there
could well be differences among rural/urban centres.
Our sample of women matched the general NWT population on smoking
coverage, with 36.1% being smokers in the Census and 30.8% being smokers
in our sample. (17) Furthermore, regardless of an under-representation
of Aboriginal women, where in the worst scenario the most at risk would
not attend Pap screening, had missing HPV results, or refused to
participate in our study, we were able to describe a number of
significant predictors for HR-HPV infection. Indeed, a notable number of
co-factors were found among Aboriginal women and not among the
non-Aboriginal group and tend to indicate that the former group have
been exposed to a different degree to risk factors that affect HPV
progression to cervical cancer that may be amenable to individual
lifestyle promotion programs.
Although different according to cultural background, overall
determinants of HR-HPV for this cohort of women are consistent with the
literature, which has identified age, multiparity, hormonal
contraceptive use, smoking, and markers of sexual activity as risk
factors for HPV infection. This study was not designed to investigate
the complex social determinant pathways of cervical cancer risk;
nonetheless, these findings can help to better target current public
health practices for women at greater risk of HPV infection and cervical
cancer. Future research should evaluate the efficacy of improvements
that have been made in terms of screening and prevention. (22)
Received: December 2, 2011
Accepted: May 21, 2012
REFERENCES
(1.) Canadian Cancer Society's Steering Committee on Cancer
Statistics. Canadian Cancer Statistics 2011. Toronto, ON: Canadian
Cancer Society, 2011.
(2.) Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal
relationship between human papillomavirus and cervical cancer. J Clin
Pathol 2002;55:244-65.
(3.) Marrett LD, Chaudhry M. Cancer incidence and mortality in
Ontario First Nations, 1968-1991 (Canada). Cancer Causes Control
2003;14:259-68.
(4.) Young TK, Kliewer E, Blanchard J, Mayer T. Monitoring disease
burden and preventive behavior with data linkage: Cervical cancer among
Aboriginal people in Manitoba, Canada. Am J Public Health
2000;90(9):1466-68.
(5.) Louchini R, Beaupre M. Cancer incidence and mortality among
Aboriginal people living on reserves and Northern villages in Quebec,
1988-2004. Int J Circumpolar Health 2008;67:445-51.
(6.) Circumpolar Inuit Cancer Review Working Group, Kelly J, Lanier
A, Santos M, Healey S, Louchini R, et al. Cancer among the Circumpolar
Inuit, 1989-2003: Patterns and trends. Int J Circumpolar Health
2008;67(5):408-20.
(7.) Canadian Partnership Against Cancer. 2010 System Performance
Report. Canadian Partnership Against Cancer, November 2010.
(8.) Annual Population Estimates by Community & Other
Characteristics of the Northwest Territories. NWT Bureau of Statistics,
2009. Available at: http://www.stats.gov.nt.ca/Statinfo/Demographics/population/popest.htlm (Accessed November 14, 2011).
(9.) Jiang Y, Brassard P, Severini A, Goleski V, Santos M, Leamon
A, et al. Type-specific prevalence of human papillomavirus infection
among women in the Northwest Territories, Canada. J Infect Public Health
2011;4(5-6):219-27.
(10.) Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer:
Epidemiology, prevention and the role of human papillomavirus infection.
CMAJ 2001;164:1017-25.
(11.) Hamlin-Douglas LK, Coutlee F, Roger M, Hanley J, Franco EL,
Brassard P. Determinants of human papillomavirus infection among Inuit
women of Northern Quebec, Canada. Sex Transm Dis 2001;37(6):377-81.
(12.) Bosch XF, Qiao Y, Castellsague X. The epidemiology of human
papillomavirus infection and its association with cervical cancer. Int J
Gynaecol Obstet 2006;94:8-21.
(13.) Special Report: Policy. The Lancet 2009;10(4):321-22.
Available at: www.thelancet.com/oncology (Accessed November 14, 2011).
(14.) Luminex xMAP Technology. Luminex Corporation, 2010. Available
at: http://www.luminexcorp.com/ (Accessed November 14, 2011).
(15.) Zubach V, Smart G, Ratnam S, Severini A. Novel
microsphere-based method for detection and typing of 46 mucosal human
papillomavirus types. J Clin Microbiol 2012;50(2):460. DOI:
10.1128/JCM.06090-11.
(16.) Rebbapragada A, Perusini S, Di Prima A, Salit I, Goleski V,
Ratnam S, et al. Evaluation of test performance characteristics and
operational parameters of 5 hpv genotyping assays. 26th International
Papillomavirus Conference, Montreal, QC, July 3-8, 2010.
(17.) Statistics Canada, 2006 Census. Population by Age and Gender
Northwest Territories & Canada. 2006. Available at:
http://www.stats.gov.nt.ca/census/2006/Age%20and%20Sex_2006.pdf
(Accessed November 14, 2011).
(18.) Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos
M, Franceschi S, et al. Prevalence and determinants of HPV infection
among Colombian women with normal cytology. Br J Cancer
2002;87(3):324-33.
(19.) Kasap B, Yetimalar H, Keklik A, Yildiz A, Cukurova K, Soylu
F. Prevalence and risk factors for human papillomavirus DNA in cervical
cytology. Eur J Obstet Gynecol Reprod Biol 2011;159(1):168-71.
(20.) Hildesheim A, Gravitt P, Schiffman MH, Kurman RJ, Barnes W,
Jones S, et al. Determinants of genital human papillomavirus infection
in low-income women in Washington, D.C. Sex Transm Dis
1993;20(5):279-85.
(21.) Demers AA, Kliewer EV, Remes O, Onysko J, Dinner K, Wong T,
Jayaraman GC. Cervical cancer among Aboriginal women in Canada. CMAJ
2012;184(7):743-44.
(22.) Elias B, Kliewer EV, Hall M, Demers AA, Turner D, Martens P,
et al. The burden of cancer risk in Canada's indigenous population:
A comparative study of known risks in a Canadian region. Int J Gen Med
2011;4:699-709.
Paul Brassard, MD, MSc, [1,2] Ying Jiang, MSc, [3] Alberto
Severini, MD, [4] Vanessa Goleski, BSc, [4] Maria Santos, MHSc, [5]
Susan Chatwood, BScN, MSc, [6,7] Candice Lys, MA, [7] Gordon Johnson,
MD, [8] Tom Wong, MD, MPH, [7,9] Andrew Kotaska, MD, [10] Kami Kandola,
MD, MPH, [5] Howard Morrison, PhD, [3] Yang Mao, PhD [3]
Author Affiliations
[1.] Division of Clinical Epidemiology, McGill University Health
Centre, Montreal, QC
[2.] Department of Medicine, McGill University, Montreal QC
[3.] Centre for Chronic Disease Prevention and Control, Public
Health Agency of Canada, Ottawa, ON
[4.] National Microbiology Laboratory, PHAC, Winnipeg, MB
[5.] Department of Health & Social Services, Yellowknife, NT
[6.] Institute for Circumpolar Health Research, Yellowknife, NT
[7.] University of Toronto, Toronto, ON
[8.] Dynacare Kasper Medical Laboratories, Edmonton, AB
[9.] Centre for Communicable Diseases and Infection Control, PHAC,
Ottawa, ON
[10.] Department of Obstetrics and Gynaecology, Stanton Territorial
Hospital, Yellowknife, NT
Correspondence: Dr. Paul Brassard, Division of Clinical
Epidemiology, McGill University Health Centre, 687 Pine Avenue West,
R4-29, Montreal, QC H3A 1A1, Tel: 514-340-7563, Fax: 514-340-7564,
E-mail:
[email protected]
Acknowledgements: This study was financially supported by the
Government of Canada International Polar Year Program and the Public
Health Agency of Canada. P. Brassard was supported by a clinician
scientist career award from the Fonds de la Recherche en Sante du Quebec
(FRSQ).
Conflict of Interest: None to declare.
Table 1. Determinants of Prevalent HR-HPV Infection
Characteristics Other HR-HPV
n (%) n (%)
Demographic
Age (years) (N=1064)
<20 44 (69.8) 19 (30.2)
20-29 235 (78.3) 65 (21.7)
30-39 222 (89.5) 26 (10.5)
40-49 240 (90.9) 24 (9.1)
50-59 149 (92.0) 13 (8.0)
60+ 24 (88.9) 3 (11.1)
Marital status (N=1077)
Married or living with
partner 647 (89.1) 79 (10.9)
Single 276 (78.6) 75 (21.4)
Educational attainment
(N=1075)
Grade school 323 (81.4) 74 (18.6)
College 273 (86.4) 43 (13.6)
University 326 (90.1) 36 (9.9)
Cultural background
(N=993)([dagger])
Non-Aboriginal 514 (90.3) 55 (9.7)
Aboriginal
First Nations 200 (79.1) 53 (20.9)
Metis 97 (80.2) 24 (19.8)
Inuit 39 (78.0) 11 (22.0)
All Aboriginals (N=998)
([dagger])
Yes 341 (79.5) 88 (20.5)
** Ratio is adjusted without Aboriginal variable
*** Ratio is adjusted without cultural background variable
Employed (N=1044)
Yes 755 (87.1) 112 (12.9)
No 139 (78.5) 38 (21.5)
Clinical
Ever had sexually
transmitted infection
(N=1033)
Yes 312 (83.9) 60 (16.1)
No 576 (87.1) 85 (12.9)
Lifetime deliveries
(N=1060)
0 308 (78.8) 83 (21.2)
1 155 (82.4) 33 (17.6)
2+ 445 (92.5) 36 (7.5)
Birth control method
(N=547)
Non-hormonal 218 (88.6) 28 (11.4)
Hormonal 234 (77.7) 67 (22.3)
Behavioural
Current smoker (N=1079)
No 655 (88.8) 83 (11.2)
Yes 269 (78.9) 72 (21.1)
Lifetime no. of sexual
partners (N=981)
<10 partners 637 (87.1) 94 (12.9)
[greater than or equal 206 (82.4) 44 (17.6)
to]10 partners
Age at first sexual
intercourse (N=1040)
11-15 232 (81.1) 54 (18.9)
16-19 524 (86.6) 81 (13.4)
20+ 136 (91.3) 13 (8.7)
No. of sexual partners in
past year (N=1053)
0 90 (92.8) 7 (7.2)
1 694 (87.2) 102 (12.8)
2-4 97 (76.4) 30 (23.6)
5+ 22 (66.7) 11 (33.3)
OR (95%)
Characteristics Crude Adjusted *
Demographic
Age (years) (N=1064)
<20 1.00(Ref) 1.00(Ref)
20-29 0.64 (0.34-1.17) 0.62 (0.35-1.12)
30-39 0.27 (0.14-0.53) 0.30 (0.15-0.61)
40-49 0.22 (0.12-0.45) 0.27 (0.13-0.55)
50-59 0.20 (0.08-0.44) 0.27 (0.12-0.61)
60+ 0.28 (0.08-1.08) 0.33 (0.08-1.33)
Marital status (N=1077)
Married or living with
partner 1.00(Ref) 1.00(Ref)
Single 2.23 (1.58-3.15) 2.07 (1.45-2.95)
Educational attainment
(N=1075)
Grade school 1.00(Ref) 1.00(Ref)
College 0.69 (0.46-1.04) 0.69 (0.45-1.06)
University 0.48 (0.31-0.74) 0.64 (0.39-1.02)
Cultural background
(N=993)([dagger])
Non-Aboriginal 1.00(Ref) 1.00(Ref) **
Aboriginal
First Nations 2.48 (1.64-3.74) 2.54 (1.65-3.91) **
Metis 2.31 (1.37-3.91) 2.24 (1.31-3.82) **
Inuit 2.46 (1.16-5.21) 2.40 (1.11-5.19) **
All Aboriginals (N=998)
([dagger])
Yes 2.41 (1.68-3.47) 2.40 (1.65-3.49) ***
** Ratio is adjusted without Aboriginal variable
*** Ratio is adjusted without cultural background variable
Employed (N=1044)
Yes 1.00(Ref) 1.00(Ref)
No 1.84 (1.22-2.78) 1.54 (0.99-2.40)
Clinical
Ever had sexually
transmitted infection
(N=1033)
Yes 1.00(Ref) 1.00(Ref)
No 0.77 (0.54-1.09) 0.99 (0.97-1.01)
Lifetime deliveries
(N=1060)
0 1.00(Ref) 1.00(Ref)
1 0.79 (0.51-1.24) 0.73 (0.46-1.17)
2+ 0.30 (0.20-0.46) 0.25 (0.16-0.39)
Birth control method
(N=547)
Non-hormonal 1.00(Ref) 1.00(Ref)
Hormonal 2.23 (1.38-3.59) 2.25 (1.38-3.66)
Behavioural
Current smoker (N=1079)
No 1.00(Ref) 1.00(Ref)
Yes 2.11 (1.49-2.98) 1.81 (1.24-2.62)
Lifetime no. of sexual
partners (N=981)
<10 partners 1.00(Ref) 1.00(Ref)
[greater than or equal 1.45 (0.98-2.14) 1.21 (0.81-1.81)
to]10 partners
Age at first sexual
intercourse (N=1040)
11-15 1.00(Ref) 1.00(Ref)
16-19 0.66 (0.45-0.97) 0.74 (0.50-1.09)
20+ 0.41 (0.22-0.78) 0.62 (0.31-1.23)
No. of sexual partners in
past year (N=1053)
0 1.00(Ref) 1.00(Ref)
1 1.89 (0.85-4.19) 1.64 (0.73-3.70)
2-4 3.97 (1.66-9.50) 2.90 (1.18-7.11)
5+ 6.43 (2.23-18.48) 5.41 (1.79-16.39)
OR (95%) = Odds ratio (95% confidence interval).
* Odds ratios are adjusted for all other characteristics.
HR-HPV = high-risk human papillomavirus; Other = HPV negative and
low-risk human papillomavirus.
** or *** = adjusted ratio using a different model (see details in
table) to avoid over-adjustment.
([dagger]) The reason for the different numbers (N=993 vs. N=998)
is that 5 Aboriginal subjects could not be classified as Metis,
First Nations or Inuit.
Table 2. Determinants of Prevalent HR-HPV Infection Among Aboriginal
Women
Characteristics Other HR-HPV
n (%) n (%)
Demographic
Age (years) (N=418)
<20 19 (59.4) 13 (40.6)
20-29 94 (70.1) 40 (29.9)
30-39 90 (85.7) 15 (14.3)
40-49 82 (91.1) 8 (8.9)
50-59 42 (87.5) 6 (12.5)
60+ 7 (77.8) 2 (22.2)
Marital status (N=427)
Married or living with
partner 220 (84.3) 41 (15.7)
Single 120 (72.3) 46 (27.7)
Educational attainment (N=424)
Grade school 181 (77.0) 54 (23.0)
College 119 (82.6) 25 (17.4)
University 38 (84.4) 7 (15.6)
Cultural background (N=422)
First Nations 200 (79.1) 53 (20.9)
Metis 97 (80.2) 24 (19.8)
Inuit 38 (79.2) 10 (20.8)
Clinical
Ever had sexually transmitted
infection (N=391)
Yes 185 (81.1) 43 (18.9)
No 127 (77.9) 36 (22.1)
Lifetime deliveries (N=415)
0 75 (64.1) 42 (35.9)
1 59 (75.6) 19 (24.4)
2+ 196 (89.1) 24 (10.9)
Birth control method (N=219)
Non-hormonal 83 (84.7) 15 (15.3)
Hormonal 82 (67.8) 39 (32.2)
Behavioural
Current smoker (N=376)
No 182 (83.5) 36 (16.5)
Yes 116 (73.4) 42 (26.6)
Lifetime no. of sexual
partners (N=352)
<10 partners 198 (81.1) 46 (18.9)
[greater than or equal to]10
partners 81 (75.0) 27 (25.0)
Age at first sexual
intercourse (N=394)
11-15 116 (73.4) 42 (26.6)
16-19 182 (83.5) 36 (16.5)
20+ 15 (83.3) 3 (16.7)
No. of sexual partners in past
year (N=407)
0 29 (90.6) 3 (9.4)
1 226 (81.0) 53 (19.0)
2-4 56 (73.7) 20 (26.3)
5+ 13 (65) 7 (35)
OR (95%)
Characteristics Crude Adjusted *
Demographic
Age (years) (N=418)
<20 1.00(Ref) 1.00(Ref)
20-29 0.62 (0.28-1.38) 0.68 (0.30-1.55)
30-39 0.24 (0.10-0.59) 0.30 (0.12-0.74)
40-49 0.14 (0.05-0.39) 0.17 (0.06-0.50)
50-59 0.21 (0.07-0.63) 0.30 (0.09-0.95)
60+ 0.42 (0.07-2.34) 0.55 (0.09-3.52)
Marital status (N=427)
Married or living with
partner 1.00(Ref) 1.00(Ref)
Single 2.06 (1.28-3.31) 1.83 (1.12-3.00)
Educational attainment (N=424)
Grade school 1.00(Ref) 1.00(Ref)
College 0.70 (0.41-1.19) 0.66 (0.38-1.15)
University 0.62 (0.26-1.46) 0.63 (0.25-1.58)
Cultural background (N=422)
First Nations 1.00(Ref) 1.00(Ref)
Metis 0.93 (0.54-1.60) 0.84 (0.47-1.51)
Inuit 0.99 (0.46-2.12) 0.96 (0.43-2.12)
Clinical
Ever had sexually transmitted
infection (N=391)
Yes 1.00(Ref) 1.00(Ref)
No 1.22 (0.74-2.01) 1.12 (0.66-1.91)
Lifetime deliveries (N=415)
0 1.00(Ref) 1.00(Ref)
1 0.58 (0.30-1.09) 0.62 (0.31-1.24)
2+ 0.22 (0.12-0.39) 0.23 (0.12-0.43)
Birth control method (N=219)
Non-hormonal 1.00(Ref) 1.00(Ref)
Hormonal 2.63 (1.35-5.14) 2.95 (1.49-5.87)
Behavioural
Current smoker (N=376)
No 1.00(Ref) 1.00(Ref)
Yes 1.69 (1.05-2.73) 1.89 (1.15-3.12)
Lifetime no. of sexual
partners (N=352)
<10 partners 1.00(Ref) 1.00(Ref)
[greater than or equal to]10
partners 1.44 (0.83-2.46) 1.45 (0.83-2.57)
Age at first sexual
intercourse (N=394)
11-15 1.00(Ref) 1.00(Ref)
16-19 0.55 (0.33-0.90) 0.52 (0.30-0.88)
20+ 0.55 (0.15-2.00) 0.70 (0.17-2.83)
No. of sexual partners in past
year (N=407)
0 1.00(Ref) 1.00(Ref)
1 2.27 (0.67-7.72) 1.87 (0.53-6.56)
2-4 3.45 (0.95-12.58) 3.04 (0.81-11.43)
5+ 5.20 (1.16-23.38) 4.59 (0.96-21.97)
OR (95%) = Odds ratio (95% confidence interval).
* Odds ratios are adjusted for all other characteristics.
HR-HPV = high-risk human papillomavirus; Other = HPV negative and
low-risk human papillomavirus.
Table 3. Determinants of Prevalent HR-HPV Infection Among
Non-Aboriginal Women
Characteristics Other HR-HPV
n (%) n (%)
Demographic
Age (year) (N=547)
<20 17 (77.3) 5 (22.7)
20-29 125 (86.2) 20 (13.8)
30-39 111 (93.3) 8 (6.7)
40-49 133 (91.7) 12 (8.3)
50-59 93 (93.0) 7 (7.0)
60+ 15 (93.8) 1 (6.3)
Marital status (N=564)
Married or living with
partner 373 (92.3) 31 (7.7)
Single 136 (85.0) 24 (15.0)
Clinical
Ever had sexually
transmitted
infection (N=558)
Yes 115 (89.1) 14 (10.9)
No 389 (90.7) 40 (9.3)
Lifetime deliveries (N=558)
0 210 (87.1) 31 (12.9)
1 82 (85.4) 14 (14.6)
2+ 211 (95.5) 10 (4.5)
Use of birth control
(N=567)
Yes 249 (88.3) 33 (11.7)
No 263 (92.3) 22 (7.7)
Behavioural
Current smoker (N=566)
No 420 (91.1) 41 (8.9)
Yes 91 (86.7) 14 (13.3)
Lifetime no. of sexual
partners (N=544)
<10 partners 382 (90.7) 39 (9.3)
[greater than or equal
to] 10 partners 109 (88.6) 14 (11.4)
Age at first sexual
intercourse (N=559)
11-15 93 (91.2) 9 (8.8)
16-19 293 (88.3) 39 (11.7)
20+ 118 (94.4) 7 (5.6)
No. of sexual partners in
past year (N=560)
0 57 (95.0) 3 (5.0)
1 406 (91.4) 38 (8.6)
2-4 33 (76.7) 10 (23.3)
5+ 9 (69.2) 4 (30.8)
OR (95%)
Characteristics Crude Adjusted *
Demographic
Age (year) (N=547)
<20 1.00(Ref) 1.00(Ref)
20-29 0.54 (0.18-1.63) 0.55 (0.17-1.73)
30-39 0.25 (0.07-0.84) 0.33 (0.09-1.20)
40-49 0.31 (0.09-0.98) 0.43 (0.13-1.49)
50-59 0.26 (0.07-0.90) 0.39 (0.10-1.46)
60+ 0.23 (0.02-2.16) 0.47 (0.05-4.93)
Marital status (N=564)
Married or living with
partner 1.00(Ref) 1.00(Ref)
Single 2.13 (1.20-3.75) 1.48 (0.79-2.78)
Clinical
Ever had sexually
transmitted
infection (N=558)
Yes 1.00(Ref) 1.00(Ref)
No 0.84 (0.44-1.61) 0.95 (0.49-1.84)
Lifetime deliveries (N=558)
0 1.00(Ref) 1.00(Ref)
1 1.16 (0.58-2.28) 1.27 (0.62-2.57)
2+ 0.32 (0.15-0.67) 0.37 (0.17-0.79)
Use of birth control
(N=567)
Yes 1.00(Ref) 1.00(Ref)
No 0.63 (0.36-1.11) 0.80 (0.44-1.46)
Behavioural
Current smoker (N=566)
No 1.00(Ref) 1.00(Ref)
Yes 1.57 (0.82-3.01) 1.23 (0.61-2.50)
Lifetime no. of sexual
partners (N=544)
<10 partners 1.00(Ref) 1.00(Ref)
[greater than or equal
to] 10 partners 1.26 (0.66-2.40) 0.80 (0.38-1.66)
Age at first sexual
intercourse (N=559)
11-15 1.00(Ref) 1.00(Ref)
16-19 1.37 (0.62-2.94) 1.73 (0.77-3.86)
20+ 0.61 (0.22-1.71) 0.85 (0.29-2.48)
No. of sexual partners in
past year (N=560)
0 1.00(Ref) 1.00(Ref)
1 1.78 (0.53-5.95) 1.71 (0.50-5.91)
2-4 5.76 (1.48-22.42) 3.95 (0.96-16.25)
5+ 8.44 (1.61-44.14) 5.18 (0.93-28.75)
OR (95%) = Odds ratio (95% confidence interval).
* Odds ratios are adjusted for all other characteristics.
HR-HPV = high-risk human papillomavirus; Other = HPV
negative and low-risk human papillomavirus.